Vaccine dark war

Even though it has made a lot of money in the epidemic, Pfizer still doesn't seem to want to miss the opportunity to bash its opponents.

On Monday night, Britain's Channel 4 released a trailer for a new documentary saying Pfizer was trying to criticize AstraZeneca's vaccine for causing cancer.

Channel 4 said Pfizer funded a lecture for public health professionals across Canada that included content showing the shortcomings of AstraZeneca vaccine "viral vector" technology.

The speech mentioned that such viral vector vaccines are at risk of "integrating chromosomes and producing tumors," suggesting that they may turn a healthy cell into a cancer cell. The speech also said that the AstraZeneca vaccine could not be used in immunocompromised people.

Pfizer responded to the allegations in the documentary, insisting that the statements cited in it were "erroneously attributed" to Pfizer, which was actually produced by a third party.

The third party is an independent Canadian scientific committee that is creating an educational program on vaccines, the spokesman said. After Canada approved Pfizer's vaccination, Pfizer funded the project at "multiple requests from Canadian medical professionals."

Pfizer's vaccine uses mRNA technology, which, once injected into the body, can transmit information to cells to make antigens. The disadvantage of this vaccine is that it needs to be stored at ultra-low temperatures and cannot be easily transported.

The vaccine developed by AstraZeneca and the University of Oxford uses a more traditional viral vector technology, which is to create a genetically modified virus to produce a spike protein similar to the new crown virus.

AstraZeneca declined to comment. Professor Andrew Pollard, head of the Oxford Vaccine Group, which developed the AstraZeneca vaccine, responded to the remarks in the speech and warned of the dangers of spreading "misinformation" about the vaccine.

"It's risky, and when people are hesitant to get vaccinated because of misinformation, their lives may be at stake."

London business media City A.M mentioned that the speech about the shortcomings of viral vector vaccines stemmed from a scientific paper written by a group of authors, one of whom had worked in the Pfizer vaccine department for several years.

As a British pharmaceutical company, AstraZeneca has fallen behind the American company Pfizer in the competition for the vaccine market.

After being found to have very rare clotting side effects and the enhancer was slightly less effective, Pfizer led the way in the number of vaccines ordered in both the UK and Europe. The UK has ordered 180 million copies of the Pfizer vaccine, almost twice as many as AstraZeneca. And 80 percent of the vaccines bought by the EU also come from Pfizer.

After the trailer aired, the Guardian posted that British ministers had reached a confidentiality clause with Pfizer and that Pfizer would not be prosecuted for anything related to the new crown virus. Any dispute must be resolved through a secret arbitration panel formed by Pfizer and the UK government.

Zain Rizvi, head of research at Public Citizen, a U.S.-based consumer advocacy group that has reviewed Pfizer's global vaccine contracts, said the UK needed to explain why it agreed to the secret arbitration process:

"It's the only high-income country we've seen that agrees with this provision." It allows pharmaceutical companies to bypass domestic legal procedures. ” "The UK government has allowed pharmaceutical companies to dictate. Why are we in such a situation that a small number of pharmaceutical companies can exert so much control over powerful governments? ”

The UK government said its vaccine contracts were commercially sensitive and could not disclose any further details.

As one of the largest suppliers of vaccines worldwide, Pfizer's huge profits are also facing increasing doubts.

Channel Four's investigation showed that an analysis by a bioengineering expert suggested that Pfizer's vaccine cost only 76 pence ($1.02) per shot to produce. The vaccine was reportedly sold to the UK government for £22 a dose. Pfizer responded that the cost of $1.02 was highly inaccurate and did not take into account the resources spent in the research and development process.

Pfizer expects to deliver 2.3 billion vaccines this year and revenues will reach $36 billion (£26.3 billion). Channel Four said that if Pfizer wants to redesign the vaccine according to The Omicron, the price will increase in the future.

Compared to Pfizer to secure its profits, AstraZeneca agreed to sell its vaccine at a cost price of £3.60 during the pandemic, with the Daily Mail saying it had "lost £21 billion in potential revenue".

AstraZeneca's decision led the World Health Organization to hail it as "the world's vaccine," but Comirnaty, a vaccine jointly developed by Pfizer and BioNTech, will be one of the most lucrative drugs in the history of medicine.

⭐ Star Wall Street sees, good content is not missed ⭐

This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation or needs of individual users. Users should consider whether any opinions, opinions or conclusions in this article are appropriate for their particular situation. The market is risky, investment needs to be cautious, please judge and make decisions independently.